The role of CDK4/6 inhibitors in early breast cancer

The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR(+)) and human epidermal growth factor receptor 2-negative (HER2(-)) breast cancer (BC), leading to a strong interest in their possible role in...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Breast
Glavni autori: Gil-Gil, Miguel, Alba, Emilio, Gavilá, Joaquín, de la Haba-Rodríguez, Juan, Ciruelos, Eva, Tolosa, Pablo, Candini, Daniele, Llombart-Cussac, Antonio
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2021
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8184648/
https://ncbi.nlm.nih.gov/pubmed/34087775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2021.05.008
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items